In the current study, we evaluate a multi-institutional cohort of lung cancer patients with all classes of BRAF mutation receiving chemotherapy, immunotherapy, or targeted therapy to evaluate treatment efficacy for each class of BRAF mutation. This evidence concerns the gene BRAF and lung carcinoma.